Clinical Trials


Combining REQORSA™ immunogene therapy with Tarceva (erlotinib)

A Phase 1/2 clinical trial evaluated REQORSA™ in combination with Tarceva in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy was conducted at MD Anderson Cancer Center. Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.

Tagrisso (osimertinib) is now considered a new standard of care in the United States for NSCLC patients with an EGFR mutation. Given this and our receipt of the FDA’s Fast Track Designation for use of REQORSA combined with Tagrisso in patients whose tumors progress on Tagrisso, we have decided to prioritize this drug combination and patient population. Therefore, we plan to initiate a Phase 1/2 clinical trial of REQORSA combined with Tagrisso, and do not intend to reopen enrollment in the current Phase I/II trial using the combination of REQORSA and Tarceva.

In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.

One patient in the Phase 2 combination trial had a Complete Response, or CR, under the Response Evaluation Criteria in Solid Tumors, or RECIST. This patient, a 58 year old female, upon enrollment in the study had metastatic NSCLC status following 6 cycles of pemetrexed and carboplatin and 2 cycles of maintenance pemetrexed with cancer progression. The patient’s tumor has EGFR exon 18 and 20 missense mutations, which are not sensitive to erlotinib. This patient had disappearance of both the lung primary tumor and the lung, liver, and lymph node metastases.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.

More information about this trial can be found at

Tarceva® is a registered trademark of Astellas and the Roche Group of companies.